We have previously noted that treatment with a sclerostin antibody, a therapeutic approach targeting Wnt signaling, appeared to be less effective in Jrt mice than in other mouse models of OI, including oim [10,12]. This evidence concerns the gene SOST and osteogenesis imperfecta.